Skip to content
Search

Latest Stories

India adopts new drug-making standards in response to overseas deaths

India adopts new drug-making standards in response to overseas deaths

The new guidelines underscore the manufacturer's accountability for product quality  

Following overseas deaths linked to Indian-made drugs since 2022, India’s Union Ministry of Health and Family Welfare has recently revised rules under Schedule M of the Drugs and Cosmetics Rules, 1945. This mandates Indian pharmaceutical companies to comply with new manufacturing standards this year.


The updated guidelines require pharmaceutical companies to inform the licensing authority about drug recalls and report product defects, deterioration, or faulty production. Previously, there was no provision for notifying the licensing authority about drug recalls.

Emphasising the manufacturer's responsibility for product quality, the new guidelines ensure products are fit for intended use, comply with licensing requirements, and do not pose risks to patients.

“Manufacturers must market a finished product only after obtaining 'satisfactory results' from ingredient tests and retaining sufficient samples for batch testing or verification,” the Health Ministry said.

In August, the Health Ministry reported an absence of testing of incoming raw materials in inspections of 162 drug factories since December 2022. Fewer than a quarter of India's 8,500 small drug factories meet international drug manufacturing standards set by the World Health Organization (WHO). Small manufacturers have a six-month deadline for WHO-GMP certification, while large units have a 12-month deadline.

Good Manufacturing Practices (GMPs) are mandatory standards ensuring product quality through control over materials, methods, machines, processes, personnel, and facilities. First incorporated in Schedule M in 1988, GMPs were last amended in June 2005.

The updated Schedule M includes 13 parts, offering GMP guidelines tailored to specific pharmaceutical drug manufacturing requirements. The amendments introduce five new categories of drugs, including those containing hazardous substances.

India, a major exporter of medicines to low/middle-income countries, requires WHO GMP certification for its pharmaceutical products. Approximately 8,500 of the country's 10,500 manufacturing units fall under the MSME category, with around 2,000 MSME units holding WHO GMP certification.

Sudarshan Jain, secretary-general of the Indian Pharmaceutical Alliance, said, "The government's revision of Schedule M is a positive and significant milestone for the Indian pharmaceutical sector. This will elevate and update the quality standards of medicines, reinforcing the industry's reputation and improving patient outcomes."

"The revised regulations of Schedule M will ensure compliance with international quality standards, benefiting both patients and the industry by promoting the manufacturing of safe, effective, and high-quality drugs,” he added.

More For You

Imported dengue reach record high, warns UKSHA

Most dengue cases were linked to travel to Southern and South-Eastern Asia.

Getty Images

Imported dengue cases hit record high – Consult your pharmacist before you travel

The UK Health Security Agency (UKSHA) has warned that imported dengue cases in England, Wales, and Northern Ireland (EWNI) have reached their highest level since dengue surveillance began in 2009.

New data from the agency reveals that 904 dengue cases were reported among returning travellers in these countries in 2024, a sharp increase from 631 in 2023.

Keep ReadingShow less
Henry Gregg named as new NPA chief executive

Henry Gregg (left) with Sir Chris Whitty

Pic credit: Henry Gregg/X

Henry Gregg named as new NPA chief executive

The National Pharmacy Association (NPA) has announced Henry Gregg will be the organisation’s new chief executive from May.

Gregg, who is currently director of external affairs at Asthma + Lung UK, replaces Paul Rees who departed in January.

Keep ReadingShow less
Kelso Pharma continues expansion with £140M funding boost

Kelso Pharma will use the funds to support further acquisitions and expand in the UK and Europe.

Getty Images

Kelso Pharma secures over £140m of acquisition funding

Kelso Pharma has secured more than £140 million of acquisition funding to support its expansion in the UK and across Europe.

The specialty pharmaceuticals business today (27) confirmed that a proportion of the funding was used for its acquisition of ALTURiX last month, a deal that doubled the size of the company’s UK business.

Keep ReadingShow less
Community pharmacist accessing GP Connect Access Record on Cegedim Rx platform

GP Connect Access Record will make a patient’s relevant medical information available to pharmacy.

Getty Images

Cegedim Rx activates GP Connect Access Record

Community pharmacy IT supplier Cegedim Rx has made GP Connect Access Record functionality available across its clinical services platform, providing registered pharmacy professionals with enhanced access to patient medical information.

The new feature, now live on Cegedim Rx’s Pharmacy Services platform, allows community pharmacies to retrieve relevant medical data when delivering NHS clinical services.

Keep ReadingShow less
Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

Patients who purchase two prescriptions per month could save more than £110 annually with a 12-month PPC.

Getty Images

Prepayment certificates helped patients avoid £837M in prescription fees, NHSBSA analysis reveals

The NHS Business Services Authority (NHSBSA) has published a new experimental analysis, estimating patient savings achieved from prescription prepayment certificates (PPCs), including Hormone Replacement Therapy (HRT) PPCs.

The report revealed that the number of Prescription Prepayment Certificates (PPCs) purchased has risen consistently over the past five years, with 3.3 million patients receiving NHS prescriptions under a PPC exemption in 2023/2024.

Keep ReadingShow less